The National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), is to partner with cancer diagnostics firm Lunit to explore innovative applications of AI in cancer research.
This collaboration aims to advance research into the tumour microenvironment and immune phenotyping, analysing NCI data to uncover insights that could drive personalised cancer care. Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials.
Lunit will analyse whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.
The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalise treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimise immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.
"This collaboration with the NCI is a testament to the power and potential of Lunit's AI-driven solutions in advancing the frontier of cancer research," said Brandon Suh, CEO of Lunit. "By applying our technologies across NCI's unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalised care to patients worldwide. We are honoured to work with one of the world's leading cancer research institutions to tackle some of the toughest challenges in oncology."
Founded in 2013, Lunit is a medical AI company using AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for cancer patients. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across more than 55 countries. Discover more at lunit.io.